The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta

Surgical resection of local disease unfeasible radically (or unaccepted by the patient, or amenable to become less demolitive, or easier, or likely more feasible, after cytoreduction) and/or metastatic disease.

ECOG Performance status 0, 1, 2 or 3

Adequate bone marrow, liver and renal function

Female patients of child-bearing potential must have negative pregnancy test.

Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study.

Written, voluntary, informed consent.

Exclusion Criteria:

Previous treatment with any other investigational or not investigational agents within 28 days of first day of study drug dosing

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00928525